p<O005).

Comment
Ironically this study shows that the thing psychiatric inpatients value most about being in hospital is their ability to leave. Of the therapeutic items, simply talking to a care giver, be they doctor or nurse, was widely regarded as the most helpful aspect of care. We emphasise that, unlike some American studies,' the sample contained many highly disturbed psychotic patients. Nevertheless, being able to confide in a member of staff was still regarded as rewarding. Contact with other patients, both informally and in ward groups, was not judged favourably. This may be unduly confrontational for some, yet for others may provide a degree of support and exchange of information unavailable elsewhere. Drug treatment was judged on average to be only "quite helpful."
The professionals' opinions were not surveyed, but from the consumer's point of view psychiatric training would be well advised to pay as much attention to "talking therapy" as it does to hospitalisation, treatment with drugs, occupational therapy, and ward rounds. We conclude that just as patients need help to understand the benefits of their drug treatment, so doctors need to be reminded that the time given to talking to the mentally ill in hospital, albeit less than one hour a week according to three quarters of our sample, is time well spent. 
Patients, methods, and results
Eight children admitted to hospital for an exacerbation of wheeze were studied. They were aged 6-13 months (mean 10-5 months), had been admitted with wheezing at least twice previously, and were thought to have benefited from nebulised ipratropium bromide given on admission. Bronchodilator treatment was withheld for at least eight hours before lung function tests were performed.
Infants were sedated with 100-120 mg chloral hydrate/kg. Measurements of airways resistance and thoracic gas volume were made with a modified total body plethysmograph. Specific conductance was calculated and oxygen saturation was monitored. Baseline measurements were made for 15 minutes after sedation.
A soft silicone Laerdal size 2 resuscitation face mask was trimmed to fit over the respiratory port of the spacer device (Nebuhaler). The device was held slightly upright and ipratropium bromide 50 mg was released into the spacer. When placed over the face of an infant it made an airtight seal. The loose valve opening allowed aerosol to be breathed in for about 10 seconds. Five repetitions resulted in a total dose of 200 mg ipratropium bromide. Lung function was measured every five minutes until the child awoke.
Airways resistance and specific conductance improved in seven of the eight patients. Overall, specific conductance at 20 minutes improved significantly compared with baseline values (p<0-01), as did airways resistance at 15 minutes (p<0002) and at 20 minutes (p<0-001). Oxygen saturation rose from a mean of 89 (SD 6)% to 92 (5)%. Mean bronchodilatation before and after giving ipratropium bromide to eight children (mean age 10-5 months). Bars indicate I SD Comment Delivery of ipratropium bromide by a metered dose inhaler with a face mask attachment is a rapid, simple, and cheap alternative to using a nebuliser. Our pilot study showed significant improvement in lung function, a result that correlated well with clinical observation. Most children tolerated the device and its face mask well, and this method was generally preferred to the aerosol with a coffee cup. The face mask seemed to act as a rebreathing chamber: the infants took increasingly large breaths during the 10 second administration, which may have enhanced aerosol deposition in the airways. Paradoxical deterioration in lung function, which has been described after nebulised asthma treatment in infancy, did not occur."4 Ipratropium bromide acts on the nose by decreasing secretions but has not been shown to alter resistance in the nasal airway. As two infants with complete nasal blockage showed a 20% improvement in specific conductance we assume that the improvement seen after ipratropium bromide was due to bronchodilatation.
A Nebuhaler has been shown to be effective in giving inhaled budesonide to young children.' We used this delivery system to give budesonide and fP2 agonists to asthmatic children aged under 2 and obtained dramatic improvement in many cases (unpublished results) .
Though this method of delivery does not replace nebulisers in severe attacks of asthma in young children, it may enable many children without access to a nebuliser to be treated successfully at home. Handicapped patients who cannot use other inhalation devices may also benefit. 
